STOCK TITAN

Summit Therapeutics (SMMT) Financials

SMMT NASDAQ
Trailing 12 months to September 30, 2026
Net Income -$832.7M n/m YoY
EPS (Diluted) -$1.06 n/m YoY
Free Cash Flow -$526.9M n/m YoY
Operating Cash Flow -$525.2M n/m YoY
Market Cap $8.4B as of Nov 18, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 14.9x on $564.7M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SMMT SEC filings page.

This page shows Summit Therapeutics Inc. (SMMT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SMMT FY2025

Summit operates as a development-stage business: research spending and financing inflows fund losses while capital investment remains minimal.

In FY2025, the net loss of $1.08B was far larger than operating cash flow of -$322.9M, so accounting results were materially affected by items beyond current-period operating cash use. Meanwhile, free cash flow of -$323.6M was close to operating cash flow because capital expenditures were only $657K, showing that cash use was tied to operations rather than physical asset investment.

FY2025 spending was split almost evenly between research and development at $537.7M and selling, general and administrative costs at $556.8M. This is a development-stage cost structure, with resources directed mainly toward research and corporate overhead rather than a profitable operating engine.

Financing cash flow of $617.5M accompanied operating cash flow of -$322.9M, indicating that the period’s cash requirements were supplemented substantially by financing inflows. At year-end, liabilities were only 12.3% of assets and the current ratio was 9.9x, indicating low stated balance-sheet leverage and substantial short-term coverage.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Summit Therapeutics Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/6

Summit Therapeutics Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Summit Therapeutics Inc. reported a net loss of $1.1B while operations used $322.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income
-$208.4M
YoYn/m
QoQn/m
5Y CAGRn/m

Summit Therapeutics Inc. reported a net loss of $208.4M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.26
YoYn/m
QoQn/m

Summit Therapeutics Inc. earned -$0.26 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$160.2M
YoYn/m
QoQn/m

Summit Therapeutics Inc. recorded an outflow of $160.2M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$150.8M
YoY-36.8%
QoQ-64.0%
5Y CAGR+13.4%

Summit Therapeutics Inc. held $150.8M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
800M
YoY+7.4%
QoQ+0.3%

Summit Therapeutics Inc. had 800M shares outstanding in Q3 2026. This represents an increase of 7.4% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-36.9%
YoY+83.7pp
QoQ-2.7pp
5Y change-17.7pp

Summit Therapeutics Inc.'s quarterly ROE was -36.9% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 83.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.7 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$169.1M
YoY+29.0%
QoQ+7.2%
5Y CAGR+53.4%

Summit Therapeutics Inc. invested $169.1M in research and development in Q3 2026. This represents an increase of 29.0% from the same quarter a year earlier. Against the prior quarter it is up 7.2%.

Capital Expenditures
$396K
YoY+457.7%
QoQ-56.4%

Summit Therapeutics Inc. invested $396K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 457.7% from the same quarter a year earlier. Against the prior quarter it is down 56.4%.

Share Buybacks

Not reported for Q3 2026.

SMMT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SMMT quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$169.1M+29.0%$157.7M-24.2%$132.6M+158.7%$147.3M+186.7%$131.1M+247.5%$208.0M+575.4%$51.3M+66.1%$51.4M+107.1%
SG&A Expenses$45.5M-55.9%$62.8M-82.6%$62.6M+301.6%$77.6M$103.1M+399.2%$360.4M+2509.4%$15.6M+35.3%N/A
Operating IncomeN/AN/AN/AN/AN/AN/AN/A-$65.6Mn/m
EBITDAN/AN/AN/AN/AN/AN/AN/A-$65.6Mn/m
Interest ExpenseN/AN/AN/AN/A$0-100.0%$0-100.0%$0-100.0%N/A
Net Income-$208.4Mn/m-$215.7Mn/m-$189.4Mn/m-$219.2Mn/m-$231.8Mn/m-$565.7Mn/m-$62.9Mn/m-$61.2Mn/m
EPS (Basic)-$0.26n/m-$0.28n/m-$0.24n/m-$0.28n/m-$0.31n/m-$0.76n/m-$0.09n/m-$0.09
EPS (Diluted)-$0.26n/m-$0.28n/m-$0.24n/m-$0.28n/m-$0.31n/m-$0.76n/m-$0.09n/m-$0.09
Diluted Shares (Avg)798M+7.4%778M+4.8%775M+5.1%N/A743M+2.3%743M+4.9%738M+5.2%N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

SMMT Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SMMT quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$692.9M+164.7%$752.2M+132.1%$647.9M+68.8%$751.2M+72.5%$261.7M-48.0%$324.0M-5.2%$383.8M+117.1%$435.6M+114.6%
Current Assets$660.7M+168.1%$720.6M+133.0%$616.6M+66.3%$720.3M+70.0%$246.5M-49.7%$309.2M-5.9%$370.8M+127.1%$423.8M+123.4%
Cash & Equivalents$150.8M-36.8%$419.4M+40.8%$106.5M-49.6%$225.3M+114.8%$238.6M+154.4%$297.9M+947.6%$211.5M+245.1%$104.9M+46.8%
Short-Term Investments$479.0Mn/m$271.3Mn/m$492.2M+228.6%$488.2M+58.8%$0-100.0%$0-100.0%$149.8M+57.0%$307.5M+167.8%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$2.0M-1.2%$2.0M-3.5%$2.0M+2.2%$2.0M+7.3%$2.0M+0.4%$2.0M+8.5%$1.9M+2.6%$1.9M-1.5%
Total Liabilities$128.2M+84.5%$122.2M+89.2%$101.9M+158.1%$92.3M+97.2%$69.5M+7.0%$64.6M-56.0%$39.5M-70.2%$46.8M-62.6%
Current Liabilities$110.2M+69.8%$103.6M+71.7%$83.3M+138.7%$73.0M+74.9%$64.9M+10.0%$60.3M-57.0%$34.9M+48.8%$41.7M+104.5%
Non-Current Liabilities$17.9M+295.4%$18.6M+336.1%$18.7M+304.3%$19.3M+280.4%$4.5M-23.4%$4.3M-35.4%$4.6M-95.8%$5.1M-95.2%
Total Equity$564.7M+193.7%$630.0M+142.8%$545.9M+58.5%$658.9M+69.5%$192.3M-56.1%$259.4M+33.0%$344.3M+678.9%$388.7M+400.4%
Retained Earnings-$2.9Bn/m-$2.7Bn/m-$2.5Bn/m-$2.3Bn/m-$2.1Bn/m-$1.8Bn/m-$1.3Bn/m-$1.2Bn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.

SMMT Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SMMT quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$159.8Mn/m-$141.1Mn/m-$122.3Mn/m-$101.9Mn/m-$93.1Mn/m-$66.7Mn/m-$61.2Mn/m-$48.7Mn/m
Depreciation & Amortization$85K+102.4%$46K+24.3%$44K+76.0%$42K+90.9%$42K+110.0%$37K+85.0%$25K-7.4%$22K-26.7%
Stock-Based Compensation$47.7M-63.5%$68.7M-85.6%$72.8M+556.0%N/A$130.8M+575.0%$478.8M+4218.0%$11.1M+16.7%N/A
Capital Expenditures$396K+457.7%$909Kn/m$245K-41.9%$164K+1071.4%$71K+22.4%$0-100.0%$422K+10450.0%$14K+600.0%
Free Cash Flow-$160.2Mn/m-$142.0Mn/m-$122.5Mn/m-$102.1Mn/m-$93.2Mn/m-$66.7Mn/m-$61.6Mn/m-$48.7Mn/m
Investing Cash Flow-$204.2Mn/m$222.9M+47.8%-$238K-100.1%-$485.2M-681.2%-$71Kn/m$150.8Mn/m$160.1M+705.7%$83.5M+37.8%
Financing Cash Flow$95.4M+182.2%$231.1M+10299.5%$3.8M-50.5%$573.8Mn/m$33.8M-83.4%$2.2M-98.9%$7.7M+1482.9%-$23.6M-477.7%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SMMT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SMMT quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-36.9%+83.7pp-34.2%+183.8pp-34.7%-16.4pp-33.3%-17.5pp-120.6%-107.7pp-218.0%-187.1pp-18.3%+80.1pp-15.7%+31.3pp
Return on Assets-30.1%+58.5pp-28.7%+145.9pp-29.2%-12.8pp-29.2%-15.1pp-88.6%-77.4pp-174.6%-156.9pp-16.4%+8.2pp-14.1%+4.0pp
Current Ratio5.99+2.2x6.96+1.8x7.41-3.2x9.87-0.3x3.80-4.5x5.13+2.8x10.63+3.7x10.15+0.9x
Liabilities-to-Equity0.23-0.1x0.19-0.1x0.19+0.1x0.140.0x0.36+0.2x0.25-0.5x0.11-2.9x0.12-1.5x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Summit Therapeutics Inc. SMMT FY2025 N/A -$1.1B N/A $8.4B —
Kymera Therapeutics, Inc. KYMR FY2025 $39.2M -$311.4M N/A $10.3B 59/100
Halozyme Therapeutics, Inc. HALO FY2025 $1.4B $316.9M 22.7% $10.9B 79/100
BioMarin Pharmaceuticals Inc BMRN FY2025 $3.2B $348.9M 10.8% $11.9B 74/100
Bio-Techne Corp. TECH FY2026 $1.2B $181.8M 15.0% $11.4B 72/100
BridgeBio Pharma, Inc. BBIO FY2025 $502.1M -$724.9M N/A $15.2B 61/100

Frequently Asked Questions

No, Summit Therapeutics Inc. (SMMT) reported a net loss of $832.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $1.1B.

Summit Therapeutics Inc. (SMMT) reported diluted earnings per share of -$1.44 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Summit Therapeutics Inc. (SMMT) has a return on equity of -163.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Summit Therapeutics Inc. (SMMT) recorded an outflow of $323.6M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Summit Therapeutics Inc. (SMMT) recorded an outflow of $322.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Summit Therapeutics Inc. (SMMT) had $751.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Summit Therapeutics Inc. (SMMT) invested $657K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Summit Therapeutics Inc. (SMMT) invested $537.7M in research and development during fiscal year 2025.

Summit Therapeutics Inc. (SMMT) had 775M shares outstanding as of fiscal year 2025.

Summit Therapeutics Inc. (SMMT) had a current ratio of 9.87 as of fiscal year 2025, which is generally considered healthy.

Summit Therapeutics Inc. (SMMT) had a liabilities-to-equity ratio of 0.14 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Summit Therapeutics Inc. (SMMT) had a return on assets of -143.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Summit Therapeutics Inc. (SMMT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $8.4B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Summit Therapeutics Inc. (SMMT) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $8.4B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Summit Therapeutics Inc. (SMMT) held $713.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $322.9M over that year. Dividing the one by the other, the reported balance equals about 27 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Summit Therapeutics Inc. (SMMT) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Summit Therapeutics Inc. (SMMT) reported a net loss of $1.1B while operations used $322.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top